+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity

  • ID: 5310290
  • Report
  • March 2021
  • Region: Europe
  • 131 pages
  • GMD Research

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer, Inc.
Europe pharmaceutical manufacturing industry accounted for $84.31 billion in 2020 and will grow by 12.9% annually over 2020-2030 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic.

Highlighted with 36 tables and 64 figures, this 131-page report “Europe Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
  • Industry Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Industry Opportunities
  • Porter’s Fiver Forces
The trend and outlook of Europe industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.

Based on Formulation, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Tablets
  • Capsules
  • Injectable
  • Sprays
  • Suspensions
  • Powders
  • Other Formulations
Based on Route of Administration, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Oral Medicine
  • Topical Medicine
  • Parenteral Medicine
  • Inhalations
  • Other Routes of Administration
Based on Age Group, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Children & Adolescents
  • Adults
  • Geriatric
Based on Therapeutic Application, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Cardiovascular Diseases
  • Pain
  • Diabetes
  • Cancer
  • Respiratory Diseases
  • Neurological Diseases
  • Orthopedics
  • Other Applications
Based on Drug Type, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Branded Prescription Drugs
  • Generic Prescription Drugs
  • OTC Drugs
Based on Distribution Channels, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • Retail Channels
  • Non-retail Channels
Based on Manufacturing Facility, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
  • In-house Facility
  • Outsourced Facility
Geographically, the following national/local markets are fully investigated:
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe (further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players.

Specifically, potential risks associated with investing in Europe pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through a proprietary Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
  • Abbott Laboratories
  • Aenova Group
  • Amgen
  • AstraZeneca
  • Catalent Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lonza Group
  • Lupin
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk
  • Pfizer, Inc.
  • Roche
  • Sanofi SA
  • Takeda
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer, Inc.
1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Industry Research Methodology
1.2.2 Industry Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Industry Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Industry Overview and Dynamics
2.1 Industry Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Industry
2.2 Major Growth Drivers
2.3 Industry Restraints and Challenges
2.4 Emerging Opportunities and Industry Trends
2.5 Porter’s Fiver Forces Analysis

3 Segmentation of Europe Industry by Formulation
3.1 Industry Overview by Formulation
3.2 Tablets
3.3 Capsules
3.4 Injectable
3.5 Sprays
3.6 Suspensions
3.7 Powders
3.8 Other Formulations

4 Segmentation of Europe Industry by Route of Administration
4.1 Industry Overview by Route of Administration
4.2 Oral Medicine
4.3 Topical Medicine
4.4 Parenteral Medicine
4.5 Inhalations
4.6 Other Routes of Administration

5 Segmentation of Europe Industry by Age Group
5.1 Industry Overview by Age Group
5.2 Children & Adolescents
5.3 Adults
5.4 Geriatric

6 Segmentation of Europe Industry by Therapeutic Application
6.1 Industry Overview by Therapeutic Application
6.2 Cardiovascular Diseases
6.3 Pain
6.4 Diabetes
6.5 Cancer
6.6 Respiratory Diseases
6.7 Neurological Diseases
6.8 Orthopedics
6.9 Other Applications

7 Segmentation of Europe Industry by Drug Type
7.1 Industry Overview by Drug Type
7.2 Branded Prescription Drugs
7.3 Generic Prescription Drugs
7.4 OTC Drugs

8 Segmentation of Europe Industry by Distribution Channels
8.1 Industry Overview by Distribution Channels
8.2 Retail Channels
8.3 Non-retail Channels

9 Segmentation of Europe Industry by Manufacturing Facility
9.1 Industry Overview by Manufacturing Facility
9.2 In-house Facility
9.3 Outsourced Facility

10 European Industry 2020-2027 by Country
10.1 Overview of European Industry
10.2 UK
10.3 France
10.4 Germany
10.5 Spain
10.6 Italy
10.7 Russia
10.8 Rest of European Industry

11 Competitive Landscape
11.1 Overview of Key Vendors
11.2 New Product Launch, Partnership, Investment, and M&A
11.3 Company Profiles
  • Abbott Laboratories
  • Aenova Group
  • Amgen
  • AstraZeneca
  • Catalent Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lonza Group
  • Lupin
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk
  • Pfizer, Inc.
  • Roche
  • Sanofi SA
  • Takeda
12 Investing in Europe Industry: Risk Assessment and Management
12.1 Risk Evaluation of Europe Industry
12.2 Critical Success Factors (CSFs)
  • Related Reports and Products
List of Tables
Table 1. Snapshot of Europe Pharmaceutical Manufacturing Industry in Balanced Perspective, 2020-2027
Table 2. Growth Rate of World Real GDP, 2017-2021
Table 3. Main Product Trends and Industry Opportunities in Europe Pharmaceutical Manufacturing Industry
Table 4. Europe Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 5. Europe Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 6. Europe Pharmaceutical Manufacturing Industry by Age Group, 2017-2027, $ bn
Table 7. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application, 2017-2027, $ bn
Table 8. Europe Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 9. Europe Pharmaceutical Manufacturing Industry by Distribution Channels, 2017-2027, $ bn
Table 10. Europe Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2017-2027, $ bn
Table 11. Europe Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn
Table 12. UK Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 13. UK Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 14. UK Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 15. France Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 16. France Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 17. France Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 18. Germany Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 19. Germany Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 20. Germany Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 21. Spain Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 22. Spain Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 23. Spain Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 24. Italy Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 25. Italy Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 26. Italy Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 27. Russia Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 28. Russia Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 29. Russia Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 30. Pharmaceutical Manufacturing Industry in Rest of Europe by Country, 2017-2027, $ bn
Table 31. Abbott Laboratories: Company Snapshot
Table 32. Abbott Laboratories: Business Segmentation
Table 33. Abbott Laboratories: Product Portfolio
Table 34. Abbott Laboratories: Revenue, 2017-2019, $ bn
Table 35. Risk Evaluation for Investing in Europe Industry, 2020-2027
Table 36. Critical Success Factors and Key Takeaways

List of Figures
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Industry Estimation
Figure 4. Europe Industry Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027
Figure 5. Europe Pharmaceutical Manufacturing Industry, 2017-2027, $ bn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Europe Pharmaceutical Manufacturing Industry
Figure 8. Primary Restraints and Impact Factors of Europe Pharmaceutical Manufacturing Industry
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Fiver Forces Analysis of Europe Pharmaceutical Manufacturing Industry
Figure 11. Breakdown of Europe Pharmaceutical Manufacturing Industry by Formulation, 2020-2027, % of Revenue
Figure 12. Contribution to Europe 2021-2027 Cumulative Revenue by Formulation, Value ($ bn) and Share (%)
Figure 13. Europe Pharmaceutical Manufacturing Industry: Tablets, 2017-2027, $ bn
Figure 14. Europe Pharmaceutical Manufacturing Industry: Capsules, 2017-2027, $ bn
Figure 15. Europe Pharmaceutical Manufacturing Industry: Injectable, 2017-2027, $ bn
Figure 16. Europe Pharmaceutical Manufacturing Industry: Sprays, 2017-2027, $ bn
Figure 17. Europe Pharmaceutical Manufacturing Industry: Suspensions, 2017-2027, $ bn
Figure 18. Europe Pharmaceutical Manufacturing Industry: Powders, 2017-2027, $ bn
Figure 19. Europe Pharmaceutical Manufacturing Industry: Other Formulations, 2017-2027, $ bn
Figure 20. Breakdown of Europe Pharmaceutical Manufacturing Industry by Route of Administration, 2020-2027, % of Revenue
Figure 21. Contribution to Europe 2021-2027 Cumulative Revenue by Route of Administration, Value ($ bn) and Share (%)
Figure 22. Europe Pharmaceutical Manufacturing Industry: Oral Medicine, 2017-2027, $ bn
Figure 23. Europe Pharmaceutical Manufacturing Industry: Topical Medicine, 2017-2027, $ bn
Figure 24. Europe Pharmaceutical Manufacturing Industry: Parenteral Medicine, 2017-2027, $ bn
Figure 25. Europe Pharmaceutical Manufacturing Industry: Inhalations, 2017-2027, $ bn
Figure 26. Europe Pharmaceutical Manufacturing Industry: Other Routes of Administration, 2017-2027, $ bn
Figure 27. Breakdown of Europe Pharmaceutical Manufacturing Industry by Age Group, 2020-2027, % of Revenue
Figure 28. Contribution to Europe 2021-2027 Cumulative Revenue by Age Group, Value ($ bn) and Share (%)
Figure 29. Europe Pharmaceutical Manufacturing Industry: Children & Adolescents, 2017-2027, $ bn
Figure 30. Europe Pharmaceutical Manufacturing Industry: Adults, 2017-2027, $ bn
Figure 31. Europe Pharmaceutical Manufacturing Industry: Geriatric, 2017-2027, $ bn
Figure 32. Breakdown of Europe Pharmaceutical Manufacturing Industry by Therapeutic Application, 2020-2027, % of Revenue
Figure 33. Contribution to Europe 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%)
Figure 34. Europe Pharmaceutical Manufacturing Industry: Cardiovascular Diseases, 2017-2027, $ bn
Figure 35. Europe Pharmaceutical Manufacturing Industry: Pain, 2017-2027, $ bn
Figure 36. Europe Pharmaceutical Manufacturing Industry: Diabetes, 2017-2027, $ bn
Figure 37. Europe Pharmaceutical Manufacturing Industry: Cancer, 2017-2027, $ bn
Figure 38. Europe Pharmaceutical Manufacturing Industry: Respiratory Diseases, 2017-2027, $ bn
Figure 39. Europe Pharmaceutical Manufacturing Industry: Neurological Diseases, 2017-2027, $ bn
Figure 40. Europe Pharmaceutical Manufacturing Industry: Orthopedics, 2017-2027, $ bn
Figure 41. Europe Pharmaceutical Manufacturing Industry: Other Applications, 2017-2027, $ bn
Figure 42. Breakdown of Europe Pharmaceutical Manufacturing Industry by Drug Type, 2020-2027, % of Revenue
Figure 43. Contribution to Europe 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%)
Figure 44. Europe Pharmaceutical Manufacturing Industry: Branded Prescription Drugs, 2017-2027, $ bn
Figure 45. Europe Pharmaceutical Manufacturing Industry: Generic Prescription Drugs, 2017-2027, $ bn
Figure 46. Europe Pharmaceutical Manufacturing Industry: OTC Drugs, 2017-2027, $ bn
Figure 47. Breakdown of Europe Pharmaceutical Manufacturing Industry by Distribution Channels, 2020-2027, % of Revenue
Figure 48. Contribution to Europe 2021-2027 Cumulative Revenue by Distribution Channels, Value ($ bn) and Share (%)
Figure 49. Europe Pharmaceutical Manufacturing Industry: Retail Channels, 2017-2027, $ bn
Figure 50. Europe Pharmaceutical Manufacturing Industry: Non-retail Channels, 2017-2027, $ bn
Figure 51. Breakdown of Europe Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2020-2027, % of Revenue
Figure 52. Contribution to Europe 2021-2027 Cumulative Revenue by Manufacturing Facility, Value ($ bn) and Share (%)
Figure 53. Europe Pharmaceutical Manufacturing Industry: In-house Facility, 2017-2027, $ bn
Figure 54. Europe Pharmaceutical Manufacturing Industry: Outsourced Facility, 2017-2027, $ bn
Figure 55. Breakdown of European Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue
Figure 56. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 57. Pharmaceutical Manufacturing Industry in UK, 2017-2027, $ bn
Figure 58. Pharmaceutical Manufacturing Industry in France, 2017-2027, $ bn
Figure 59. Pharmaceutical Manufacturing Industry in Germany, 2017-2027, $ bn
Figure 60. Pharmaceutical Manufacturing Industry in Spain, 2017-2027, $ bn
Figure 61. Pharmaceutical Manufacturing Industry in Italy, 2017-2027, $ bn
Figure 62. Pharmaceutical Manufacturing Industry in Russia, 2017-2027, $ bn
Figure 63. Pharmaceutical Manufacturing Industry in Rest of Europe, 2017-2027, $ bn
Figure 64. Growth Stage of Europe Industrial Robot Software Industry over the Forecast Period
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Abbott Laboratories
  • Aenova Group
  • Amgen
  • AstraZeneca
  • Catalent Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Lonza Group
  • Lupin
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk
  • Pfizer, Inc.
  • Roche
  • Sanofi S.A.
  • Takeda
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll